- Home
- MYNZ vs HCWB Comparison
MYNZ vs HCWB Comparison
Compare MYNZ & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- HCWB
- Stock Information
- Founded
- MYNZ 2021
- HCWB 2018
- Country
- MYNZ Germany
- HCWB United States
- Employees
- MYNZ N/A
- HCWB N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- HCWB Health Care
- Exchange
- MYNZ Nasdaq
- HCWB Nasdaq
- Market Cap
- MYNZ 7.6M
- HCWB 8.4M
- IPO Year
- MYNZ 2021
- HCWB 2021
- Fundamental
- Price
- MYNZ $2.04
- HCWB $4.26
- Analyst Decision
- MYNZ Buy
- HCWB Strong Buy
- Analyst Count
- MYNZ 2
- HCWB 1
- Target Price
- MYNZ $14.00
- HCWB $35.00
- AVG Volume (30 Days)
- MYNZ 185.7K
- HCWB 305.5K
- Earning Date
- MYNZ 08-05-2025
- HCWB 08-13-2025
- Dividend Yield
- MYNZ N/A
- HCWB N/A
- EPS Growth
- MYNZ N/A
- HCWB N/A
- EPS
- MYNZ N/A
- HCWB N/A
- Revenue
- MYNZ $893,991.00
- HCWB $1,445,145.00
- Revenue This Year
- MYNZ $26.06
- HCWB $178.36
- Revenue Next Year
- MYNZ $4.97
- HCWB N/A
- P/E Ratio
- MYNZ N/A
- HCWB N/A
- Revenue Growth
- MYNZ N/A
- HCWB N/A
- 52 Week Low
- MYNZ $1.34
- HCWB $3.55
- 52 Week High
- MYNZ $19.00
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- MYNZ 57.11
- HCWB 40.26
- Support Level
- MYNZ $1.89
- HCWB $4.10
- Resistance Level
- MYNZ $2.25
- HCWB $4.49
- Average True Range (ATR)
- MYNZ 0.22
- HCWB 0.31
- MACD
- MYNZ 0.05
- HCWB 0.09
- Stochastic Oscillator
- MYNZ 76.14
- HCWB 27.30
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.